Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.10.2023 | Case report

Agammaglobulinaemia-tyrosine-kinase-inhibitors/cyclophosphamide/fludarabine

Hepatitis-B virus reactivation: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Yan Z, et al. Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review. [Review]. Journal of Microbiology, Immunology and Infection 56 : 747-756, No. 4, Aug 2023. Available from: URL: http://doi.org/10.1016/j.jmii.2023.04.003 Yan Z, et al. Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review. [Review]. Journal of Microbiology, Immunology and Infection 56 : 747-756, No. 4, Aug 2023. Available from: URL: http://​doi.​org/​10.​1016/​j.​jmii.​2023.​04.​003
Metadaten
Titel
Agammaglobulinaemia-tyrosine-kinase-inhibitors/cyclophosphamide/fludarabine
Hepatitis-B virus reactivation: case report
Publikationsdatum
01.10.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-47093-5

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Antineoplastics

Case report

Telmisartan

Case report

Vancomycin